Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 肿瘤
/
经典阳性药
小分子阳性药 细胞周期 维生素D相关/核受体 肿瘤干细胞 PPARs
/
PPAR
降血脂 心血管系统
/ Fenofibrate

非诺贝特 /Fenofibrate {[allProObj[0].p_purity_real_show]}

货号：A763996 同义名： NSC-281319

Fenofibrate is an agonist of PPARα (EC50 = 30 μM) and an inhibitor of CYP2C19 (IC50 = 0.2 μM) and CYP2B6 (IC50 = 0.7 μM). Fenofibrate is a fibric acid derivative and used to treat hypercholesterolemia and hypertriglyceridemia.

Fenofibrate 化学结构 CAS号：49562-28-9
Fenofibrate 化学结构
CAS号：49562-28-9
Fenofibrate 3D分子结构
CAS号：49562-28-9
Fenofibrate 化学结构 CAS号：49562-28-9
Fenofibrate 3D分子结构 CAS号：49562-28-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Fenofibrate 纯度/质量文件 产品仅供科研

货号：A763996 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 PPARα ↓ PPARβ/δ ↓ PPARγ ↓ PPARδ ↓ 其他靶点 纯度
Fenofibric acid ✔ 98%
GW6471 ++

PPARα, IC50: 0.24 μM

 		99%+
GSK3787 ++

PPARδ, pIC50: 6.6

 		++

PPARδ, pIC50: 6.6

 		99%+
FH535 ✔ 98%+
GW9662 +++

PPARα, IC50: 32 nM

 		+++

PPARγ, IC50: 3.3 nM

 		98%
T0070907 ++++

PPARγ, IC50: 1 nM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Fenofibrate 生物活性

描述 Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, these enzymes are involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Peroxisome proliferator-activated receptors (PPARs) belong to the steroid hormone receptor superfamily. PPARs mediate the action of peroxisome proliferators, and affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses. Fenofibrate is a PPARα agonist, and also a Cytochrome P450 Epoxygenase 2C (CYP2C) inhibitor. In vitro assessment revealed that the EC50 of Fenofibrate to CYP2C was 2.39±0.4 μM, while the EC50 of Fenofibrate to PPARα was 30 μM, suggesting higher affinity to CYP2C[3]. Based on fluorometric CYP450 inhibition assays, Fenofibrate also inhibited CYP2C19, CYP2C8 and CYP2C9 with the IC50s of 0.2 μM, 4.8 μM and 9.7 μM, respectively[4]. In animal experiments, Fenofibrate was administrated at the dose of 150 mg/kg orally in C57BL/6J (B6) or B6 × 129S4 mice for 8 days in the studies of withdrawal, loss of righting reflex, startle reflex, response to novelty, and EtOH clearance, and for the duration of the experiment in the studies of conditioned place preference and conditioned taste aversion. The results revealed that Fenofibrate decreased the novelty response, increased acute EtOH withdrawal severity, and increased EtOH-induced conditioned taste aversion， while EtOH-induced conditioned place preference was not altered. EtOH clearance was increased by fenofibrate. Response to novelty, acute withdrawal, and EtOH clearance show sex differences and could contribute to the reduced EtOH consumption following fenofibrate administration[5].

Fenofibrate 动物研究

Dose Rat: 100 mg/kg[3] (p.o.), 30 mg/kg[4] (p.o.)
Administration p.o.

Fenofibrate 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00673881 Dyslipidemia Phase 1 Phase 2 Completed - United States, Illinois ... 展开 >> Radiant Research, 515 N State St, #2700 Chicago, Illinois, United States, 60610 收起 <<
NCT00261352 Type 2 Diabetes Phase 3 Terminated(The development pro... 展开 >>gram has been terminated) 收起 << - -
NCT00195793 Hyperlipidemia Phase 3 Completed - -

Fenofibrate 参考文献

[1]Gong Y, Shao Z, et al. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Nov;13:201-211.

[2]Schelleman H, Han X, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48.

[3]Gong Y, Shao Z, Fu Z, Edin ML, Sun Y, Liegl RG, Wang Z, Liu CH, Burnim SB, Meng SS, Lih FB, SanGiovanni JP, Zeldin DC, Hellström A, Smith LEH. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. EBioMedicine. 2016 Nov;13:201-211. doi: 10.1016/j.ebiom.2016.09.025. Epub 2016 Sep 30. PMID: 27720395; PMCID: PMC5264653.

[4]Schelleman H, Han X, Brensinger CM, Quinney SK, Bilker WB, Flockhart DA, Li L, Hennessy S. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol. 2014 Sep;78(3):639-48. doi: 10.1111/bcp.12353. PMID: 24548191; PMCID: PMC4243914.

[5]Blednov YA, Black M, Benavidez JM, Stamatakis EE, Harris RA. PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption. Alcohol Clin Exp Res. 2016 Mar;40(3):563-71. doi: 10.1111/acer.12972. Epub 2016 Feb 9. PMID: 26857541; PMCID: PMC4775356.

Fenofibrate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.86mL

2.77mL

1.39mL

27.71mL

5.54mL

2.77mL

Fenofibrate 技术信息

CAS号49562-28-9
分子式C20H21ClO4
分子量 360.83
别名 NSC-281319
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature
溶解度

DMSO: 105 mg/mL(290.99 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

2% DMSO+40% PEG 300+2% Tween 80+water 10 mg/mL

Tags: Fenofibrate | NSC-281319 | Cardiovascular System | Reduce Blood Lipid | PPAR | AmBeed-信号通路专用抑制剂 | Fenofibrate 纯度/质量文件 | Fenofibrate 亚型比较 | Fenofibrate 生物活性 | Fenofibrate 动物研究 | Fenofibrate 临床数据 | Fenofibrate 参考文献 | Fenofibrate 实验方案 | Fenofibrate 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z